Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
7452- CYN,    Cynaropicrin inhibits pancreatic cancer cell viability and disrupts cellular redox homeostasis
- in-vitro, PC, PANC1
tumCV↓, Thiols↓, NF-kB↓, ROS↑,
7451- CYN,    Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF‐κB, and Nrf‐2 signaling pathways in vitro
- in-vitro, Melanoma, A375
TumCP↓, Casp3↑, Apoptosis↑, TumCMig↓, TumCI↓, ERK↓, NF-kB↓, ROS↓, HO-1↑, NRF2↑, Bcl-2↓, NF-kB↓, other↝,
7450- CYN,    Cynaropicrin Induces Cell Cycle Arrest and Apoptosis by Inhibiting PKM2 to Cause DNA Damage and Mitochondrial Fission in A549 Cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
PKM2↓, P53↑, PARP↓, TumCCA↑, selectivity↑, DNAdam↑, NRF2↓, NQO1↓, TrxR↓, Trx↓, ROS↑, MMP↓, Cyt‑c↑, Casp3↑, Apoptosis↑,
7449- CYN,    Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines
- in-vitro, lymphoma, U937 - in-vitro, AML, Jurkat
TumCP↓, selectivity↑, Apoptosis↑, TumCCA↑, DNAdam↑, eff↓, ROS↑, tumCV↓,
7448- CYN,    Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs
- in-vitro, Pca, DU145
GSH↓, STAT3↓, Bcl-2↓, survivin↓, cl‑PARP↑, ChemoSen↑,
7447- CYN,    Antiproliferative Effects of Cynaropicrin on Anaplastic Thyroid Cancer Cells
- in-vitro, Thyroid, 8505C - in-vitro, Thyroid, CAL62 - in-vitro, Thyroid, SW1736
tumCV↓, TumCCA↑, NF-kB↓, p‑STAT3↓, lipid-P↑, ROS∅,
7446- CYN,    Promotion of HeLa cells apoptosis by cynaropicrin involving inhibition of thioredoxin reductase and induction of oxidative stress
- in-vitro, Cerv, HeLa
ROS↑, Apoptosis↑, TrxR↓,
7445- CYN,    Cynaropicrin Shows Antitumor Progression Potential in Colorectal Cancer Through Mediation of the LIFR/STATs Axis
- vitro+vivo, CRC, RKO - in-vitro, CRC, HCT116 - in-vitro, CRC, DLD1
tumCV↓, STAT↓, LIFR/CD118↓, STAT3↓, STAT4↑, TumCG?, cl‑PARP1↑, Bcl-2↓, BAX↑, STAT3↓, Dose↝, TumVol↓, TumW↓, toxicity↓,
7444- CYN,    The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress
- in-vitro, GBM, U87MG
TumCG↓, Dose↝, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, TumAuto↑, p‑ERK↓, NF-kB↓, ChemoSen↑, eff↓,
7442- CYN,    Cynaropicrin induces the apoptosis of colorectal cancer cells by elevating reactive oxygen species and activating the JNK/p38 MAPK
- in-vitro, CRC, HCT116
Apoptosis↑, p‑JNK↑, p‑MAPK↑, ROS↑, eff↓, TumCCA↑, Bcl-2↓,
7441- CYN,    Cynaropicrin attenuates UVB-induced oxidative stress via the AhR-Nrf2-Nqo1 pathway
- in-vitro, Nor, NA
*ROS↓, *NRF2↑, *Inflam↓, *IL6↓, *TNF-α↓, *AhR↑, *NQO1↑,
7440- CYN,    Suppression of endoplasmic reticulum stress-dependent autophagy enhances cynaropicrin-induced apoptosis via attenuation of the P62/Keap1/Nrf2 pathways in neuroblastoma
- vitro+vivo, neuroblastoma, NA
AntiTum↑, Apoptosis↑, TumAuto↑, TumCG↓,
7439- CYN,    Cynaropicrin Induces Reactive Oxygen Species-Dependent Paraptosis-Like Cell Death in Human Liver Cancer Cells
- in-vitro, Liver, Hep3B
tumCV↓, mtDam↑, ER Stress↑, i-Ca+2↑, ROS↑, Alix/AIP‑1↓, eff↓,
7438- CYN,    Cynaropicrin Suppresses Cell Proliferation by Inducing Mitophagy through p38 MAPK-Mediated Mitochondrial ROS Generation in Human Hepatocellular Carcinoma Cells
- in-vitro, HCC, NA
tumCV↓, TumAuto↑, selectivity↑, mt-ROS↑, MMP↓, LC3B↑, Beclin-1/ATG6↓, p62↓, PINK1↑, PARK2↑, eff↓, p‑MAPK↑,
7437- CYN,    Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma
- in-vitro, Mye, AMO1 - in-vivo, Mye, NA - in-vitro, Mye, KMS11 - in-vitro, Mye, JJN3 - in-vitro, Mye, MolP8 - in-vitro, Mye, L363 - in-vitro, Mye, H929
tumCV↓, cMyc↓, STAT3↓, Akt↓, ERK↓, TumCCA↑, DNAdam↑, PARP1↑, AIF↑, TumCG↓,
6264- Cyste,    Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine
- Review, Nor, NA
*TG2/TGase↓, eff↑,
6263- Cyste,    Mechanism for the inhibition of transglutaminase 2 by cystamine
- Study, Nor, NA
*neuroP↑, TG2/TGase↓,
6262- Cyste,    A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety
- Trial, Nor, NA
*eff↑,
6261- Cyste,    A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
eff↑, eff↑,
6260- Cyste,    A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
- Trial, Nor, NA
*toxicity?,
6259- Cyste,    Therapeutic Applications of Cysteamine and Cystamine in Neurodegenerative and Neuropsychiatric Diseases
- Review, AD, NA - Review, Park, NA
*ROS↓, *neuroP↑, *BDNF↑, *NRF2↑, *BBB↑, *HSPs↑, *GSH↑, *TG2/TGase↓, Aβ↓,
6258- Cyste,    Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo
- Review, NA, NA
*TG2/TGase↓,
6257- Cyste,    Cystamine induces AIF-mediated apoptosis through glutathione depletion
- vitro+vivo, Var, NA
AIF↑, GSH↓, neuroP↑,
6256- Cyste,    Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis
- in-vitro, Kidney, Caki-1
TG2/TGase↓, necrosis↑, selectivity↑,
6255- Cyste,    Cysteamine Suppresses Cancer Cell Invasion and Migration in Glioblastoma through Inhibition of Matrix Metalloproteinase Activity
- in-vitro, GBM, NA
MMPs↓, MMP2↓, MMP9↓, MMP14↓, TumCI↓, TumCMig↓, Dose↓,
4333- Cyste,    Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription
- vitro+vivo, AD, NA
*NRF2↑, *ARE↑, *neuroP↑, *BDNF↑, *GSH↑,
4332- Cyste,    Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases
- in-vivo, Park, NA - in-vivo, HD, NA
*neuroP↑, *other↝, *other↝,
4331- Cyste,    Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
- in-vivo, HD, NA - NA, AD, NA
*BDNF↑, *neuroP↑, *TG2/TGase↓,
1871- DAP,    Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth
- in-vitro, AML, U937 - in-vivo, AML, NA
TumCP↓, Apoptosis↑, TumCG↓, PDK1 / PDPK1↓, cl‑PARP↑, Bcl-xL↓, Bcl-2↓, Beclin-1/ATG6↓, ATG3↓, PI3K↓, Akt↓, eff↑,
6686- DAP,    Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer
- in-vivo, Pca, NA
PDK1 / PDPK1↓, TumCP↓, TumCMig↓, BioAv↓, BioAv↑, Apoptosis↑, Casp3↑, Casp7↑, Glycolysis↓,
6684- DAP,  GB,    Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells
- vitro+vivo, NSCLC, H1975
PDK1 / PDPK1↓, eff↑, EGFR↓, Apoptosis↑,
6685- DAP,    Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1
- in-vitro, Lung, H1975
PDKs↓, selectivity∅, MMP↓, Apoptosis↑, lactateProd↓, ROS↑,
6593- DAS,    Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
TumCP↓, TumCI↓, TumMeta↓, eff↑, Src↓,
6592- DAS,    Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- Trial, CML, NA
Dose↝, other↝, OS↑,
6591- DAS,    Dasatinib in solid tumors
- Review, Var, NA
Src↓, PDGF↓, ABL1↓, BioAv↝, Half-Life↝, Dose↝, eff↑,
6590- DAS,    Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
- in-vitro, Pca, NA
Src↓, ABL1↓, BioAv↑, TumCG↓, Dose↓, TumCA↓, TumCMig↓, TumCI↓,
6589- DAS,    Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells
- in-vitro, CLL, NA
Src↓, ABL1↓,
6588- DAS,    Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Src↓, ABL1↓,
6683- DCA,    Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts
- Review, Var, NA
PDK1 / PDPK1↓, lactateProd↓, Apoptosis↑, TumCP↓, selectivity↑, other↝, Dose↝, BioAv↑, Half-Life↓, Glycolysis↓, OXPHOS↑, Casp↑, i-pH↓, COX2/PTGS2↑, Hif1a↓, angioG↓, HMG-CoA↓, GSTZ1↓, OCR↑, lipoGen↓, fatigue↓, survivin↓, miR-375↑, eff↓, CSCs↓, TumAuto↑, mTOR↓, TumCI↓, TumVol↓, TumW↓, ATP↓, Warburg↓, eff↑, e-pH↑, eff↑, eff↑, other↝, RadioS↑, toxicity↓, Dose↝, eff↑, eff↑, eff↑, toxicity↝, eff↓,
6682- DCA,  QC,    Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer
- in-vivo, HNSCC, MEER
PDK1 / PDPK1↓, lactateProd↓, GlucoseCon↓, tumCV↓, mTOR↓, Apoptosis↑, ROS↑, TumCG↓, pH↑, cl‑PARP↑, Casp3↑, DNAdam↑, p‑γH2AX↑, eff↓, OS↑,
6681- DCA,    Dichloroacetate (DCA) in Cancer Care
PDK1 / PDPK1↓, Apoptosis↑, ROS↑, lactateProd↓, Dose↝, eff↝, toxicity↓, NP/CIPN↑, Dose↝, *BioAv↑, *Half-Life↓, GSTZ1↝, Glycolysis↓, OXPHOS↑, MPT↑, Cyt‑c↑, AIF↑, Casp↑, CSCs↓, Remission↑, ChemoSen↑, RadioS↑, toxicity↑,
6680- DCA,    The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation
- NA, Laryn, FaDu
PDH↓, PDKs↓, OCR↑,
6679- DCA,    GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial
- Trial, Melanoma, NA
PDK1 / PDPK1↓, Half-Life↝, eff↑, NP/CIPN↑, Dose↝, Half-Life↝,
6678- DCA,  Cisplatin,    Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
- Trial, HNSCC, NA
PDK1 / PDPK1↓, OS∅, lactateProd↓, toxicity↝, FAO↑,
4901- DCA,  Sal,    Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer
- Review, NSCLC, NA
Glycolysis↓, OXPHOS↑, PDKs↓, ROS↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, RadioS↑, TumAuto↑, mTOR↓, LC3s↓, p62↑, TumCG↓, OS↑, toxicity↝, ChemoSen↑, eff↑, eff↑, Ferritin↓, CSCs↓, EMT↓, ROS↑, Cyt‑c↑, Casp3↑, ER Stress↑, selectivity↑, eff↑, TumCG↓,
5194- DCA,    Metabolic modulation of glioblastoma with dichloroacetate
- vitro+vivo, GBM, NA
MMP↓, mt-ROS↑, Apoptosis↑, CSCs↓, Hif1a↓, P53↑, angioG↓, toxicity↓, PDKs↓,
5195- DCA,  Rad,    Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells
- in-vitro, BC, 4T1 - in-vitro, BC, EMT6
PDKs↑, ROS↑, p‑PDH↓, ECAR↓, lactateProd↓, selectivity↓, RadioS↑,
5196- DCA,    Dichloroacetate induces apoptosis in endometrial cancer cells
- in-vitro, Var, NA
selectivity↑, MMP↓, survivin↓, Ca+2↓, P53↑, PDK1 / PDPK1↓, PDH↑, Glycolysis↓, OXPHOS↑, ROS↑, Cyt‑c↑, Apoptosis↑, Casp↑, tumCV↓, PUMA↑,
5197- DCA,  5-FU,    Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism
- in-vitro, GC, NA
Glycolysis↓, ChemoSen↑, PDK1 / PDPK1↓,
1878- DCA,  5-FU,    Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer
- in-vitro, CRC, LS174T - in-vitro, CRC, LoVo - in-vitro, CRC, SW-620 - in-vitro, CRC, HT-29
tumCV↓, eff↑, PDKs↓, lactateProd↓, Glycolysis↓, mitResp↑, TumCCA↑, Bcl-2↓, BAX↑, Casp3↑,

Showing Research Papers: 2951 to 3000 of 8269
Prev Page 60 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

LIFR/CD118↓, 1,   miR-375↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 2,   GSTZ1↓, 1,   GSTZ1↝, 1,   HO-1↑, 1,   lipid-P↑, 1,   NQO1↓, 1,   NRF2↓, 1,   NRF2↑, 1,   OXPHOS↑, 4,   PARK2↑, 1,   ROS↓, 1,   ROS↑, 14,   ROS∅, 1,   mt-ROS↑, 2,   Thiols↓, 1,   Trx↓, 1,   TrxR↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ABL1↓, 4,   AIF↑, 3,   ATP↓, 1,   mitResp↑, 1,   MMP↓, 6,   MPT↑, 1,   mtDam↑, 1,   OCR↑, 2,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,   ECAR↓, 1,   FAO↑, 1,   GlucoseCon↓, 2,   Glycolysis↓, 7,   HMG-CoA↓, 1,   lactateProd↓, 8,   lipoGen↓, 1,   PDH↓, 1,   PDH↑, 1,   p‑PDH↓, 1,   PDK1 / PDPK1↓, 10,   PDKs↓, 5,   PDKs↑, 1,   PKM2↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 17,   BAX↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp↑, 3,   Casp3↑, 6,   Casp7↑, 1,   Cyt‑c↑, 5,   p‑JNK↑, 1,   p‑MAPK↑, 2,   necrosis↑, 1,   PUMA↑, 1,   survivin↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 4,   tumCV↓, 10,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↓, 1,   Beclin-1/ATG6↓, 2,   LC3B↑, 1,   LC3s↓, 1,   p62↓, 1,   p62↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 4,   P53↑, 3,   PARP↓, 1,   cl‑PARP↑, 3,   PARP1↑, 1,   cl‑PARP1↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 4,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   mTOR↓, 3,   PI3K↓, 1,   Src↓, 5,   STAT↓, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   STAT4↑, 1,   TumCG?, 1,   TumCG↓, 8,  

Migration(tgid=13) ⓘ

Alix/AIP‑1↓, 1,   Ca+2↓, 1,   i-Ca+2↑, 1,   MMP14↓, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   PDGF↓, 1,   TG2/TGase↓, 2,   TumCA↓, 1,   TumCI↓, 5,   TumCMig↓, 4,   TumCP↓, 6,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↑, 1,   NF-kB↓, 5,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1,   e-pH↑, 1,   i-pH↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen↑, 5,   Dose↓, 2,   Dose↝, 9,   eff↓, 8,   eff↑, 18,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 3,   RadioS↑, 4,   selectivity↓, 1,   selectivity↑, 7,   selectivity∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   Ferritin↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   fatigue↓, 1,   neuroP↑, 1,   NP/CIPN↑, 2,   OS↑, 3,   OS∅, 1,   Remission↑, 1,   toxicity↓, 4,   toxicity↑, 1,   toxicity↝, 3,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 142

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ARE↑, 1,   GSH↑, 2,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 2,  

Cell Death(tgid=5) ⓘ

AhR↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSPs↑, 1,  

Migration(tgid=13) ⓘ

TG2/TGase↓, 4,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   eff↑, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 5,   toxicity?, 1,  
Total Targets: 20

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page